Affinity is an important determinant of the anti-trypanosome activity of nanobodies

PLoS Negl Trop Dis. 2012;6(11):e1902. doi: 10.1371/journal.pntd.0001902. Epub 2012 Nov 15.

Abstract

Background: The discovery of Nanobodies (Nbs) with a direct toxic activity against African trypanosomes is a recent advancement towards a new strategy against these extracellular parasites. The anti-trypanosomal activity relies on perturbing the highly active recycling of the Variant-specific Surface Glycoprotein (VSG) that occurs in the parasite's flagellar pocket.

Methodology/principal findings: Here we expand the existing panel of Nbs with anti-Trypanosoma brucei potential and identify four categories based on their epitope specificity. We modified the binding properties of previously identified Nanobodies Nb_An05 and Nb_An33 by site-directed mutagenesis in the paratope and found this to strongly affect trypanotoxicity despite retention of antigen-targeting properties. Affinity measurements for all identified anti-trypanosomal Nbs reveal a strong correlation between trypanotoxicity and affinity (K(D)), suggesting that it is a crucial determinant for this activity. Half maximal effective (50%) affinity of 57 nM was calculated from the non-linear dose-response curves. In line with these observations, Nb humanizing mutations only preserved the trypanotoxic activity if the K(D) remained unaffected.

Conclusions/significance: This study reveals that the binding properties of Nanobodies need to be compatible with achieving an occupancy of >95% saturation of the parasite surface VSG in order to exert an anti-trypanosomal activity. As such, Nb-based approaches directed against the VSG target would require binding to an accessible, conserved epitope with high affinity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Protozoan / immunology*
  • Antibodies, Protozoan / pharmacology
  • Antibody Affinity
  • Mice
  • Mice, Inbred C57BL
  • Microbial Viability / drug effects
  • Single-Domain Antibodies / immunology*
  • Single-Domain Antibodies / pharmacology
  • Trypanosoma brucei brucei / drug effects
  • Trypanosoma brucei brucei / immunology*

Substances

  • Antibodies, Protozoan
  • Single-Domain Antibodies

Grants and funding

This work was supported by the InterUniversity Attraction Poles Programme [IUAP, P6 and P7] of the Belgian Science Policy, the Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen and the EU/FP7 ERC starting grant “NANOSYM” [282312]. This project was also supported by ITM and VUB fundings. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.